跳至主要内容
临床试验/EUCTR2010-020083-38-FR
EUCTR2010-020083-38-FR进行中(未招募)1 期

A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged =13 Years

F. Hoffmann-La Roche Ltd0 个研究点目标入组 200 人开始时间: 2010年9月17日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male and female adults and adolescents, 13 years of age and older
  • Diagnosis of influenza by virology testing or clinical diagnosis based on symptoms suggestive of influenza
  • Less than or equal to 96 hours between the onset of influenza-like illness and first dose of study medication
  • Patient is willing and able to comply with study requirements and give consent, or, if applicable, consent may be given by a parent, legal guardian or legal representative
  • Female patients who are pregnant may be enrolled only if the potential benefit justifies the potential risk to the fetus
  • Female patients who are lactating may be enrolled only if the potential benefit for the lactating mother justifies the potential risk to the breast-fed infant
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients with clinical evidence of severe hepatic decompensation at the time of randomization
  • Electrocardiogram showing acute ischemia or significant arrhythmia • Allergy to test medication
  • Patients taking probenicid medication within 7 days before starting study medication
  • Participation in a clinical trial or expanded access trial with an investigational drug in the 4 weeks prior to randomization

研究者

相似试验

进行中(未招募)
不适用
A study to assess the safety of Oseltamivir administered in the vein for the treatment of flu (Influenza) in patients of at least 13 years of age.
EUCTR2010-020083-38-DKF. Hoffmann-La Roche Ltd200
进行中(未招募)
1 期
A study to assess the safety of Oseltamivir administered in the vein for the treatment of flu (Influenza) in patients of at least 13 years of age.Treatment of Influenza [seasonal or pandemic (H1N1) 2009]MedDRA version: 14.0Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2010-020083-38-DEF. Hoffmann-La Roche Ltd118
进行中(未招募)
不适用
A study to assess the safety of Oseltamivir administered in the vein for the treatment of flu (Influenza) in patients of at least 13 years of age.Treatment of Influenza [seasonal or pandemic (H1N1) 2009]MedDRA version: 14.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2010-020083-38-LTF. Hoffmann-La Roche Ltd200
进行中(未招募)
不适用
A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged = 13 Years. - ND
EUCTR2010-020083-38-ITF.Hoffmann-La Roche Ltd200
进行中(未招募)
1 期
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu StraiInfluenza
EUCTR2016-001008-49-Outside-EU/EEAF. Hoffmann-La Roche AG400